Regorafenib
8 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients (NCT05426811) | China Medical University, China | 2022-07-01 |
| Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma (NCT05048017) | Peking Union Medical College Hospital | 2021-10-01 |
| cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC (NCT05025592) | Peking University Cancer Hospital & Institute | 2021-09-10 |
Track Regorafenib automatically
Every clearance here is in the API, with alerts when new ones post.